6-K ·Filed Apr 16, 2026

PHAR

Pharming Group N.V.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001828316-26-000021
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine governance announcement. Traders should note the AGM date and agenda, but no immediate trading action is warranted based on this filing alone. Monitor for any unexpected developments during the actual meeting.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PHAR ▼ -20.54% at T+60d
NEUTRAL call ✗ call lost -20.54% · α vs SPY -27.59% · entry $17.33 → $13.77
Entry anchored
Apr 15, 02:00 PM ET
via exchange tick
T+1d
+0.06%
call +0.06% · α -1.16%
$17.34
settled 6mo ago
T+5d
-3.98%
call -3.98% · α -4.97%
$16.64
settled 5mo ago
T+20d
-25.16%
call -25.16% · α -30.97%
$12.97
settled 5mo ago
T+60d
-20.54%
call -20.54% · α -27.59%
$13.77
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Pharming Group N.V. announced the date and agenda for its 2026 Annual General Meeting of Shareholders (AGM). The meeting will include proposals to appoint KPMG N.V. as auditor, amend non-executive director fees, and renew authorizations for share issuance and repurchase. This is a routine corporate governance filing.

Key Facts

  • Pharming Group N.V. announced its 2026 Annual General Meeting of Shareholders (AGM) will be held on May 28, 2026.
  • The AGM agenda includes appointing KPMG N.V. as external auditor for 2026-2028.
  • The agenda includes proposals to amend fees for Non-Executive Directors.
  • The agenda includes renewing authorizations for the Board to issue and repurchase shares.

Financial Impact

The filing contains no new financial data. The share issuance and repurchase authorizations are routine renewals.

Risk Factors

  • Routine filing with no material financial risk disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001828316-26-000021
Document: 0001828316-26-000021-index-headers.html0001828316-26-000021
Document: 0001828316-26-000021-index.html0001828316-26-000021
Document: 0001828316-26-000021.txt0001828316-26-000021
7 reports for PHAR
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+20▲ +10.43%Jun 4, 2026
Filters
Rows
Reports for PHAR — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
6-K
BULLISH ★ 7/10
$11.21 $10.55▼ −5.89%▼ −5.67%$9.91 (−11.60%)
Aug 13, 2026
7w ago
6-K
BULLISH ★ 6/10
$12.35 $11.68▼ −5.43%▼ −3.46%$9.91 (−19.76%)
Jun 4, 2026
17w ago
6-K
BULLISH ★ 7/10
$12.47 $12.88▲ +3.29%▲ +5.84%$9.91 (−20.53%)
May 28, 2026
18w ago
6-K
NEUTRAL ★ 3/10
$13.66 $12.24▼ −10.40%▼ −10.35%$9.91 (−27.45%)
May 22, 2026
18w ago
6-K
BULLISH ★ 7/10
$13.62 $12.28▼ −9.84%▼ −11.05%$9.91 (−27.24%)
Apr 16, 2026
24w ago
6-K
NEUTRAL ★ 3/10
$17.33 $16.64▼ −3.98%▼ −4.97%$9.91 (−42.82%)
Mar 27, 2026
27w ago
6-K
BULLISH ★ 8/10
$16.31 $16.50▲ +1.16%▼ −2.70%$9.91 (−39.24%)
Showing 7 of 7

US Market Status

Market Open — Closes in 2h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access